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Abstract
Background: Colorectal cancer, if detected early, has greater than 90% 5-year survival. However, survival has
been shown to vary across racial/ethnic groups in the United States, despite the availability of early detection
methods.
Methods: This study evaluated the joint effects of sociodemographic factors, tumor characteristics, census-based
socioeconomic status (SES), treatment, and comorbidities on survival after colorectal cancer among and within
racial/ethnic groups, using the SEER-Medicare database for patients diagnosed in 1992–1996, and followed
through 1999.
Results: Unadjusted colorectal cancer-specific mortality rates were higher among Blacks and Hispanic males than
whites (relative rates (95% confidence intervals) = 1.34 (1.26–1.42) and 1.16 (1.04–1.29), respectively), and lower
among Japanese (0.78 (0.70–0.88)). These patterns were evident for all-cause mortality, although the magnitude
of the disparity was larger for colorectal cancer mortality. Adjustment for stage accounted for the higher rate
among Hispanic males and most of the lower rate among Japanese. Among Blacks, stage and SES accounted for
about half of the higher rate relative to Whites, and within stage III colon and stages II/III rectal cancer, SES
completely accounted for the small differentials in survival between Blacks and Whites. Comorbidity did not
appear to explain the Black-White differentials in colorectal-specific nor all-cause mortality, beyond stage, and
treatment (surgery, radiation, chemotherapy) explained a very small proportion of the Black-White difference.
The fully-adjusted relative mortality rates comparing Blacks to Whites was 1.14 (1.09–1.20) for all-cause mortality
and 1.21 (1.14–1.29) for colorectal cancer specific mortality. The sociodemographic, tumor, and treatment
characteristics also had different impacts on mortality within racial/ethnic groups.
Conclusion: In this comprehensive analysis, race/ethnic-specific models revealed differential effects of covariates
on survival after colorectal cancer within each group, suggesting that different strategies may be necessary to
improve survival in each group. Among Blacks, half of the differential in survival after colorectal cancer was
primarily attributable to stage and SES, but differences in survival between Blacks and Whites remain unexplained
with the data available in this comprehensive, population-based, analysis.
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Background
Cancers of the colon and rectum are the second leading
cause of cancer deaths among men and women in the
United States (US), responsible for more than 57,000
deaths each year [1,2]. Despite declines in the incidence
and mortality of colorectal cancer, survival following
diagnosis has improved only modestly over the past 15
years [1-4]. However, early detection measures are availa-
ble for colorectal cancer, and if caught in the earliest stage,
more than 90% of patients will survive beyond five years.
Decreased survival is well documented among Blacks in
relation to Whites, with most recent population-based
studies showing a 30–50% higher rate of disease-specific
mortality after diagnosis [5-13], and the largest racial/eth-
nic differentials seen among stage I and II cancers [5]. Of
particular concern, the disparity in mortality rates
between Blacks and Whites have widened over time
[14,15]. The reasons for these differences are not well
understood. The limited number of studies that have
examined access and quality of cancer treatment, such as
socioeconomic status [9-13,16], general treatment modal-
ities [10], health insurance [13] and provider characteris-
tics [9] have reported inconsistent results as to the extent
to which these factors explained the Black-White differ-
ences in survival. Although comorbid illness and tumor
aggressiveness have been shown to independently affect
survival, their impact on racial/ethnic survival differences
have not been well addressed.
There have been fewer population-based studies of color-
ectal survival in other racial/ethnic groups [5,6,17-20]. In
a recent analysis of SEER data examining differences sur-
vival across detailed racial/ethnic groups, Chien et al
found that, in addition to Blacks, higher hazard ratios for
stage-adjusted colorectal cancer-specific deaths were seen
among American Indians, Hawaiians, and Mexicans [5].
The authors speculated that the remaining decreased sur-
vival in these groups may be due to socioeconomic status
and/or comorbidities. Choe et al found, in an analysis
based on imputed SEER birthplace data, that foreign-born
Asians were slightly more likely than US-born to present
with advanced stage and have decreased stage-adjusted
survival [17]. As colorectal cancer occurrence is known to
be related to factors associated with living in a more devel-
oped country (sedentary lifestyle, high consumption of
meats and saturated fats, and low consumption of fruits
and vegetables [21,22]), disease burden in Hispanic and
Asian racial/ethnic groups is expected to increase as they
become acculturated to the lifestyle more common in the
US [22-24]. It is important to also emphasize that "Asian"
and "Hispanic" are very heterogeneous categories, each
consisting of a variety of separate and discrete racial/eth-
nic groups. Thus, the understanding of issues related to
colorectal cancer is a priority for these populations. Cur-
rently, in SEER data, although detailed Hispanic origin is
collected, more than half of Hispanic patients are coded as
"other or not otherwise specified" for detailed Hispanic
origin, thus analyses for detailed Hispanic subgroups is
not advisable. However, detailed Asian categories are col-
lected and are mostly accurate and reliable [25], thus anal-
yses for detailed Asian subgroups is possible.
Our study aimed to address the gaps in understanding of
factors associated with racial/ethnic survival patterns by
jointly considering patient and clinical factors including
sociodemographics, tumor characteristics, neighborhood
SES, treatment, and comorbidities, in a representative and
large population of Medicare-eligible patients (aged 65
and older, who comprise about 70% of all colorectal
patients [26]). Using the SEER-Medicare linked database,
our analyses extend those of Chien et al by including data
on area-based socioeconomic status and comorbidities.
We also considered the effects of these factors on survival
within each of six racial/ethnic groups [27].
Methods
Data Source
We used the linked Surveillance, Epidemiology, and End
Results (SEER) – Medicare database, which combines data
from the NCI SEER Program of population-based regis-
tries that collect demographic, clinical, and vital status
information for persons with cancer, with Medicare
claims for covered health care services, including hospital-
izations [28-30]. The registries in the SEER Program, at the
time of this analysis, included the states of Connecticut,
Hawaii, Iowa, New Mexico and Utah, and the metropoli-
tan areas of Atlanta, Detroit, San Francisco/Oakland, Seat-
tle/Puget Sound, San Jose/Monterey, and Los Angeles,
representing approximately 14% of the US population
[26]. The latter two registries joined the SEER program in
1992. Medicare is the primary source of health insurance
for 97% of Americans age 65 years and older. All recipi-
ents are enrolled in Part A benefits, which cover inpatient
care in hospitals and other facilities; ninety-five percent of
beneficiaries also subscribe to Part B, which covers addi-
tional services including physician services [29]. These are
the sources of admissions data used in this analysis.
The linkage of SEER with Medicare data, which is based
on a deterministic matching algorithm using social secu-
rity number, name, sex, and date of birth [28], captured
93% of patients age 65 and older at diagnosis in the SEER
database [29]. This analysis used data from the linkage
conducted in 1999. Recipients under age 65 who received
Medicare benefits for end-stage renal disease or for other
reasons were excluded.BMC Cancer 2007, 7:193 http://www.biomedcentral.com/1471-2407/7/193
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Study Subjects
Patients living in a SEER catchment area and aged 65 and
older when diagnosed with a microscopically-confirmed,
first primary, malignant tumor of the colon or rectum
(ICD-O-2 codes C180–C209, C260, excluding histologies
9590–9989) during the period January 1, 1992 through
December 31, 1996 were included. This period of time
was included for consistency with availability of physician
claims data and 1990 Census data, which are provided as
part of the linked database. We further excluded about
10% of cases that were coded as lymphomas, sarcomas,
melanomas, carcinoids, or tumors of the squamous cell,
appendix, or unspecified sites; those with invalid survival
time (including those diagnosed at death or autopsy);
those with unknown cause of death; and those of
unknown or other race/ethnicity (N = 208), leaving us a
final sample of 41,901 subjects. The numbers of patients
in each racial/ethnic group are shown in Table 1.
Analytical Variables
Race/ethnicity was classified according to the categories
shown in the tables. These categories were created to be as
specific as possible while preserving adequate numbers
for stability of estimates. Information on race/ethnicity,
age and year of diagnosis, SEER registry, marital status,
tumor characteristics, and radiation were obtained from
the SEER portion, or Patient Entitlement and Diagnosis
Summary File (PEDSF), of the linked database. SEER reg-
istry staff members abstract these data elements from
medical records at hospitals, doctor's offices and other
facilities. In addition to the data originally obtained from
SEER, the PEDSF also included data on area-based socio-
economic measures (poverty, percentage of high school
graduates, median income) of the 1990 Census tract of
residence as well as the urban/rural status of the county of
residence.
Patient information on race and ethnicity were extracted
from the SEER database, which are primarily based on
patients' hospital medical records. Despite variable hospi-
tals practices and policies in recording these information
[31,32], the quality of these data have been shown to be
generally good [25,33]. Racial/ethnic categories were
defined to be consistent with prior publications using
SEER data [6,19,34]. Chinese, Japanese, and Filipinos
were classified regardless of Hispanic ethnicity. Racial/
ethnic groups with fewer than 200 patients were excluded;
these groups include American Indians/Alaskan Natives,
Native Hawaiians and other Pacific Islanders, and other
smaller Asian subgroups. Patients coded in the SEER data
as Hispanic on the basis of surname only were not classi-
fied as Hispanic, because of prior research showing mis-
classification of surname-only classifications.
Census socioeconomic variables corresponding to the
tract of patients' addresses at diagnosis are available in the
linked SEER-Medicare data; more detailed geographic
level measures are not available. Social epidemiologists
have noted that while the sizes of the populations covered
by census tract units are large and thus limited for concep-
tualizations of neighborhoods, they have also acknowl-
edged that in the absence of better data, this level of
geographical aggregation is acceptable and standard prac-
tice for examining neighborhood SES [35,36]. In fact,
prior publications of national SEER data have examined
contextual SES at an even broader level of geography [37-
41]. We examined measures of census tract SES (poverty,
education, and income, as defined in Table 1) and also
computed a composite measure (SES index) summing the
quartiles of each individual measure. Quartiles are based
on distributions of the entire study population. This SES
index ranged from 1–4, with 1 representing the highest
SES quartile and 4 representing the lowest SES. Overall,
there were 2937 (7%) patients with missing SES data,
ranging from 7% among Whites to 20% among Filipinos;
it is likely that these patients could not be reliability geoc-
oded to a census tract. In the absence of individual-level
SES data in the cancer registry and Medicare databases,
area-based SES measures are useful in this study for exam-
ining the impact of neighborhood socioeconomic status
on cancer survival. These measures have been shown to be
independently predictive of an array of health outcomes
[36,42-54]. In this study, the area-based SES measures are
not meant to serve as a proxy for individual-level SES.
We used claims information on inpatient hospitalizations
and physicians visits occurring 12 months before and 4
months after diagnosis for classification of comorbidities
using the Charlson comorbidity index [55,56]. The Charl-
son index assigns weights from 1 to 6 corresponding to
disease severity, for 19 medical conditions. The weights
are then summed to provide an overall score. For this
analysis we excluded metastatic and in-situ colon and rec-
tum cancers from the comorbidity index and adapted
standard inclusion criteria, which specifies that physician
admissions are valid comorbidities only if they occur on
two or more claims more than 30 days apart [30,57,58].
Patients with no admissions records during this period
were considered to have had no comorbidities. Medicare
only requires claims data for care covered by fee-for-serv-
ice, or indemnity, insurance; thus claims data for HMO
enrollees were often not available in this database. We
conducted the analyses that incorporate comorbidity
information excluding those aged 65 at diagnosis [59]
and did not find that our results changed from those
including this group. As the numbers of patients with two
or more comorbidities in most of the racial/ethnic groups
are small (Table 1), we analyzed comorbidity in subse-
quent models as none versus any.BMC Cancer 2007, 7:193 http://www.biomedcentral.com/1471-2407/7/193
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Table 1: Percent distribution of colorectal cancer patients, demographic and clinical characteristics by race/ethnicity (N = 41,901), 
SEER, 1992–1996
Characteristic Non-Hispanic
White 
Non-Hispanic
Black 
Hispanic1  Chinese Japanese Filipino 
N = 34,164 N = 3,184  N = 2,061 N = 881 N = 1,116 N = 495
Gender
Male 47 43 50 57 54 56
Female 53 57 50 43 46 44
Year of diagnosis
1992–93 41 40 38 38 40 36
1994–96 59 60 62 62 60 64
SEER region2
SFBA 15 14 22 50 10 35
Connecticut 16 6 5 0 0 1
Detroit 13 32 1 1 0 0
Hawaii 1 0 0 13 60 33
Iowa 16 2 1 -- 0 --
New Mexico 3 1 18 0 0 --
Seattle 11 3 1 4 5 4
Utah 3 0 2 0 1 --
Atlanta 4 13 1 1 -- 0
LA 18 29 49 31 24 27
20%+ below poverty (N = 38,964) 7 52 25 20 9 11
Below poverty quartiles3 (N = 38,964)
1 (highest SES) 28 5 11 16 30 18
2 27 7 16 22 28 29
32 6 1 4 2 3 2 3 2 1 2 8
4 (lowest SES) 19 74 50 38 21 25
Non-HS quartiles4 (N = 38,964)
1 (highest SES) 28 6 11 20 19 11
22 7 1 1 1 7 2 0 2 2 2 1
32 6 1 5 1 9 2 1 2 8 2 2
4 (lowest SES) 18 69 53 39 31 47
Median income quartiles5 (N = 38,964)
1 (highest SES) 27 6 14 29 36 30
22 6 1 1 2 3 2 6 3 2 3 7
32 5 2 1 3 0 2 0 2 0 1 7
4 (lowest SES) 22 62 33 26 12 16
SES index6 quartiles (N = 38,964)
1 (highest SES) 34 7 15 29 34 21
2 21 7 13 13 20 24
32 9 1 9 2 7 2 7 3 1 3 4
4 (lowest SES) 16 67 45 32 15 22BMC Cancer 2007, 7:193 http://www.biomedcentral.com/1471-2407/7/193
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Unknown SES 7 10 12 17 13 20
Married at diagnosis
Yes 52 37 51 66 64 64
No 45 59 46 32 35 34
Unknown 2 4 3 2 1 1
Age at diagnosis (mean ± S.D.)
65–69 (67.1 ± 1.4) 20 26 30 19 27 27
70–74 (72.0 ± 1.4) 24 26 25 25 29 22
75–79 (77.0 ± 1.4) 23 22 19 26 20 19
80+ (84.9 ± 4.1) 33 27 26 31 23 32
Site (location)
Proximal colon 46 49 42 36 36 27
Distal colon 28 30 27 35 35 38
Rectum 26 21 31 29 29 34
AJCC stage at diagnosis
Stage I 24 21 22 21 27 23
Stage II 32 28 31 31 29 25
Stage III 22 22 24 27 26 28
Stage IV 15 20 17 13 12 16
Unknown 7 9 7 8 6 7
Grade/differentiation
Well 10 10 9 7 6 6
Moderate 60 63 61 65 72 68
Poor/None 19 14 19 19 13 15
Unknown 12 13 11 9 9 11
Surgery7
None/NC Direct 9 14 9 10 6 11
Partial 7 6 6 6 8 7
GT Part/LT Tot 72 69 70 74 75 71
Total 11 11 14 10 11 10
Surgery, NOS 0.2 0.2 0.3 0.2 0.1 0.4
Radiation8
None 90 91 86 90 91 89
Any 9 7 11 8 8 9
Unknown 1 1 2 1 1 2
Chemotherapy9
None 92 96 87 89 95 92
Any 8 4 13 11 5 8
Received guideline treatment, stage III colon cancer (N = 
6940)10
16 10 23 21 10 15
Received guideline treatment, stages II and III rectal cancer 
(N = 4626) 10
83 1 0 7 4 4
Table 1: Percent distribution of colorectal cancer patients, demographic and clinical characteristics by race/ethnicity (N = 41,901), 
SEER, 1992–1996 (Continued)BMC Cancer 2007, 7:193 http://www.biomedcentral.com/1471-2407/7/193
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Received guideline treatment, stage III colon + stages II/III 
rectal cancer (N = 11,566) 10
13 8 17 15 8 10
Comorbidity11
None 68 68 72 82 77 80
12 2 1 9 1 9 1 4 1 6 1 3
2 or more 10 13 9 5 5 7
All of the comparisons are statistically significant across races/ethnicities (Chi-Square p < 0.001).
1 Hispanic = 2053 Whites, 8 Blacks
2 SFBA: San Francisco Bay Area (San Francisco-Oakland & San Jose-Monterey regions), LA: Los Angeles region
3 Percent of census tract residents living below poverty level
4 Percent of persons age 25+ years with less than 12 years of education in census tract
5 Median household income in census tract
6 SES index = summation of quartiles of poverty + high school graduate + median income
7 Colorectal cancer-directed surgery with or without radiation. NC = Non-cancer directed; GT Part/LT Tot = greater than partial/less than total; 
Surgery, NOS = surgery, not otherwise specified
8 Any radiation = beam, implants, isotopes, or combination; unknown = refused, recommended but don't know if administered, and unknown if 
administered
9 Chemotherapy assessed using data from the physician supplier files
10 For stage III colon cancer, guideline treatment is receipt of surgery and chemotherapy; for stages II and III rectal cancer, guideline treatment is 
receipt of surgery, chemotherapy, and radiation
11 Comorbidity measured with Charlson Index using data from physician supplier and inpatient hospitalization files
Table 1: Percent distribution of colorectal cancer patients, demographic and clinical characteristics by race/ethnicity (N = 41,901), 
SEER, 1992–1996 (Continued)
SEER-modified AJCC (American Joint Committee on
Cancer) staging scheme, 3rd edition (1988+) was used to
define tumor stage at diagnosis. AJCC stage is determined
based on detailed information in SEER on extent of dis-
ease – tumor size, nodal involvement, and extent of
metastasis. SEER registries collect information regarding
treatment administered during the first four months post-
diagnosis. For surgery, patients were classified as having
received partial colectomy if they underwent segmental
resection (cecectomy, appendectomy, sigmoidectomy,
partial resection of transverse colon and flexures, ileo-
colectomy, enterocolectomy, and partial/subtotal colec-
tomy), laser surgery, polypectomy, cryosurgery, or
fulguration; and total/hemicolectomy if they received
hemicolectomy or greater, all right/left and portion of
transverse colectomy, total colectomy, non-specified
colectomy, or colectomy plus partial/total removal of
other organs. Information on receipt of radiation was
obtained from SEER records; prior research has shown
that SEER data alone on radiation is >95% complete
[60,61]. Chemotherapy was obtained from physician
claims data (for a period of six months after diagnosis
[62]) and coded into the categories shown in Table 1.
Patients without physician claims data during this time
period were coded as not having received chemotherapy.
Warren et al previously documented that physician claims
alone captures about 70% of chemotherapy administra-
tion for colon and rectal cancers [62]. In this cohort, the
vast majority of patients (92%) receiving chemotherapy
received 5-fluorouracil. We also defined treatment as
receiving guideline therapy according to the NIH consen-
sus conference standards, which includes surgery plus
adjuvant chemotherapy for stage III colon cancer and sur-
gery plus adjuvant chemotherapy and radiation for stages
II and III rectal cancer [63-67]. We have included each of
these treatment modalities as separate variables into the
models to assess their independent impact on survival;
this practice is consistent with prior analyses based on
cancer registry data [5,68-70]. In addition, within stage III
colon and stages II and III rectal cancer, we have adjusted
for one single variable representing receipt of guideline
therapy.
Follow-up
Date and cause of death information were obtained from
SEER. Registries conduct active and passive follow-up of
cancer patients for vital status using linkages with state
and national death indices, Centers for Medicare and
Medicaid Services files, driver's license registration files,
voter registration files, Social Security Administration
files, national credit agency records, and other databases,
as well as contact with patients, hospitals and physicians'
offices. Through linkage of the SEER-Medicare data to a
more recent version of the SEER public use data, patients
in this analysis were followed for vital status through
December 31, 1999, which is also the date of censoring
for patients who were last known to be alive. Underlying
cause of death was abstracted from death certificates, and
deaths assigned International Classification of Disease –
Ninth Revision (ICD-9) codes 153.0–154.1 were identi-
fied as due to colon or rectal cancer.BMC Cancer 2007, 7:193 http://www.biomedcentral.com/1471-2407/7/193
Page 7 of 19
(page number not for citation purposes)
Statistical Analyses
The Mantel-Haenszel chi-square test was used to compute
p-values for differences in distribution of patient and clin-
ical characteristics across racial/ethnic groups. Five-year
cause-specific survival probabilities and associated 95%
confidence intervals (CI) were computed based on Kap-
lan-Meier survival curves. This analysis focuses on cause-
specific (colorectal) survival as the outcome; however,
racial/ethnic patterns were generally similar with the two
types of outcomes – all-cause survival and colorectal spe-
cific-survival. Cox proportional hazards regression was
used to compute relative rates of dying of colorectal cancer
specifically and of all causes. Proportionality of hazards
was checked graphically and confirmed use of the Cox
regression models. Cells with less than five cases are not
shown for privacy purposes. Models were computed with
parameters representing each non-White racial/ethnic
group to assess mortality difference compared to non-His-
panic Whites (Tables 2 (unadjusted survival), 3 (cause-
specific mortality), and 4 (all-cause mortality)); inde-
pendent variables were included in turn to assess the rela-
tive impact on the racial/ethnic differences. Models were
also computed for each racial/ethnic group (Tables 5
(cause-specific mortality) and 6 (all-cause mortality)) to
assess the relative effects of the sociodemographic and
clinical characteristics on mortality within groups. To
assess whether differences in the parameter estimates were
significant across racial/ethnic groups, we compared the
log likelihood ratios for a main effects model with race/
ethnicity and the independent prognostic factors with a
model containing an interaction term of race/ethnicity
and the prognostic factor of interest.
Human subjects issues were reviewed and approved by
the Northern California Cancer Center Institutional
Review Board.
Results
Characteristics of study population
Table 1 shows the distribution of patient and clinical char-
acteristics, by race/ethnicity. There were proportionally
fewer males than females among Blacks and more males
than females among Asians. Two-thirds of Blacks, about
half of Hispanics, and one-third of Chinese lived in lower
SES Census tracts. Whites and Japanese were least likely to
be living in the lowest SES tracts. Chinese, Japanese, and
Filipinos were most likely to be married, while Blacks
were the least likely.
Whites and Blacks had higher proportions of proximal
colon tumors than rectal cancers. In contrast, Filipinos
had more distal and rectal tumors. Blacks, Hispanics, and
Filipinos were more likely than other racial/ethnic groups
to be diagnosed with stage III and IV disease, and Whites,
Hispanics, and Chinese were more likely to be diagnosed
with poorly or undifferentiated tumors. Proportionally
more Blacks received no surgery or no cancer directed sur-
gery (14%). Only about 10% overall received radiation
treatment, varying from 7% among Blacks to 11% among
Hispanics. From 4–5% of Blacks and Japanese to 13% of
Hispanics had chemotherapy. Relatively fewer Blacks and
Japanese received guideline treatment for stage III colon
cancer compared to Hispanics and Chinese, and relatively
fewer Blacks, Japanese, and Filipinos received guideline
treatment for stages II and III rectal cancer. Approximately
one-third of Whites, Blacks, and Hispanics had one or
more comorbid conditions, compared to smaller percent-
ages in the other groups. Proportionally more Blacks had
two or more comorbid conditions than the other groups,
particularly the three Asian subgroups.
Table 2 shows unadjusted survival estimates by sex and
race/ethnicity. Both Black males and females experienced
Table 2: Unadjusted survival estimates, by sex and race/ethnicity (N = 41,901), SEER, 1992–1996
Survival Non-Hispanic
White
Non-Hispanic
Black
Hispanic Chinese Japanese Filipino
Males (N = 19,979) 16,213 1,356 1,032 498 601 279
Colorectal cancer deaths, N (%) 5119 (32) 531 (39) 375 (36) 154 (31) 157 (26) 88 (32)
5-Year colorectal survival (95% 
CI)
0.65 (0.64–0.65) 0.55 (0.52–0.58) 0.60 (0.56–0.63) 0.67 (0.62–0.71) 0.71 (0.67–0.75) 0.64 (0.58–0.70)
All cause deaths, N (%) 9116 (56) 854 (63) 569 (55) 252 (51) 293 (49) 153 (55)
5-Year all cause survival (95% CI) 0.45 (0.44–0.46) 0.37 (0.35–0.40) 0.46 (0.41–0.49) 0.51 (0.46–0.56) 0.53 (0.49–0.57) 0.47 (0.41–0.53)
Females (N = 21,922) 17,951 1,828 1,029 383 515 216
Colorectal cancer deaths, N (%) 5865 (33) 723 (40) 33 (32) 132 (34) 146 (28) 66 (31)
5-Year colorectal survival
(95% CI)
0.64 (0.63–0.65) 0.55 (0.53–0.58) 0.64 (0.60–0.67) 0.62 (0.57–0.67) 0.69 (0.64–0.73) 0.68 (0.60–0.74)
All cause deaths, N (%) 9722 (54) 1125 (62) 538 (52) 185 (48) 226 (44) 99 (46)
5-Year all cause survival (95% CI) 0.47 (0.47–0.48) 0.39 (0.37–0.41) 0.48 (0.45–0.51) 0.52 (0.47–0.57) 0.57 (0.52–0.61) 0.54 (0.46–0.60)BMC Cancer 2007, 7:193 http://www.biomedcentral.com/1471-2407/7/193
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decreased 5-year survival compared to other groups.
Other notable racial/ethnic variations in survival include
decreased disease-specific survival among Hispanic males.
Some heterogeneity in survival among Asian subgroups
was evident: Filipino males and Chinese females experi-
enced slightly decreased disease-specific and overall sur-
vival.
Factors associated with survival/mortality
Race/ethnic mortality relative to Whites
Table 3 shows the relative rates of dying of colorectal can-
cer for each racial/ethnic group compared to Whites.
Racial/ethnic patterns, relative to Whites, were similar
between males and females and are thus combined, with
the exception of Hispanics, for whom gender differences,
in relation to Whites, were evident and thus presented
separately. Compared to Whites, colorectal cancer-specific
mortality rates were 33% higher among Blacks and 16%
higher among Hispanic males. Mortality rates among Jap-
anese were lower than Whites, while mortality among
Hispanic females, Chinese and Filipinos was comparable
to Whites. Among Blacks, adjusting for disease character-
istics (primarily stage) reduced the hazard ratio from 1.32
to 1.26, and while adjusting independently for education
level, poverty, and income further reduced the hazard
ratio, mortality among Blacks was still 16% significantly
higher than Whites. Among Hispanic males, adjustment
for disease characteristics (primarily stage) appeared to
account for their higher mortality compared to Whites.
Among Japanese, the significantly lower mortality rate
compared to Whites was partially attributable to disease
characteristics but mostly to sociodemographic factors
(primarily SEER region). Comorbidity did not affect
racial/ethnic differences in colorectal cause-specific mor-
tality rates.
Table 4 shows the relative rates of dying of any cause for
each racial/ethnic group compared to Whites. The 23%
higher rate of death among Blacks compared to Whites
was partially attributable to disease characteristics, socio-
economic status, and treatment (to a lesser extent),
although the all-cause mortality rate among Blacks
remained significantly higher than the rate among Whites
even after adjusting for all of these factors simultaneously.
Table 3: Relative rates (and 95% confidence intervals) of dying of colorectal cancer for each racial/ethnic group (relative to non-
Hispanic Whites), SEER, 1992–1996
Variables in model Non-Hispanic
Black 
N = 3,009
Hispanic 
N = 1,951
Chinese 
N = 851
Japanese 
N = 1,094
Filipino 
N = 479
Male 
N = 1,032
Female 
N = 1,029
1. Race/ethnicity 1.33 (1.26–1.42) 1.16 (1.04–1.29) 0.98 (0.88–1.10) 0.98 (0.87–1.11) 0.79 (0.70–0.88) 0.99 (0.84–1.16)
2. Race/ethnicity + 
sociodemographics1
1.32 (1.24–1.41) 1.12 (1.00–1.26) 1.02 (0.91–1.15) 1.06 (0.93–1.19) 0.94 (0.82–1.09) 1.09 (0.92–1.30)
3. Race/ethnicity + 
sociodemographics & disease 
characteristics2
1.26 (1.18–1.34) 1.01 (0.90–1.13) 0.93 (0.82–1.04) 1.02 (0.90–1.16) 0.97 (0.84–1.12) 0.96 (0.81–1.13)
4. Race/ethnicity + 
sociodemographics, disease 
characteristics, & treatment3
1.21 (1.14–1.29) 1.01 (0.90–1.14) 0.94 (0.83–1.06) 0.97 (0.86–1.10) 0.98 (0.85–1.13) 0.91 (0.76–1.07)
5. Race/ethnicity + 
sociodemographics, disease 
characteristics, treatment, & 
education
1.16 (1.09–1.24) 0.98 (0.87–1.10) 0.92 (0.81–1.04) 0.95 (0.84–1.08) 0.96 (0.83–1.11) 0.88 (0.74–1.05)
6. Race/ethnicity + 
sociodemographics, disease 
characteristics, treatment, & 
income
1.17 (1.09–1.25) 0.99 (0.89–1.12) 0.93 (0.83–1.05) 0.96 (0.85–1.09) 0.98 (0.85–1.12) 0.90 (0.76–1.07)
7. Race/ethnicity + 
sociodemographics, disease 
characteristics, treatment, & 
poverty
1.16 (1.09–1.25) 0.99 (0.88–1.11) 0.93 (0.83–1.05) 0.96 (0.84–1.08) 0.98 (0.85–1.12) 0.90 (0.76–1.06)
8. Race/ethnicity + 
sociodemographics, disease 
characteristics, treatment, & 
comorbidities
1.21 (1.14–1.29) 1.01 (0.90–1.13) 0.94 (0.83–1.05) 0.97 (0.86–1.10) 0.98 (0.85–1.13) 0.91 (0.77–1.08)
1 sociodemographic factors = age and marital status at diagnosis, sex, year of diagnosis, and SEER region
2 disease characteristics = stage, grade, site
3 treatment = surgery, radiation, chemotherapyBMC Cancer 2007, 7:193 http://www.biomedcentral.com/1471-2407/7/193
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Comorbidity did not affect the all-cause mortality differ-
ence between Black and White colorectal cancer patients.
Chinese and Japanese experienced significantly lower all-
cause mortality compared to Whites; for both groups,
their more favorable mortality rates were attributable to
sociodemographic factors. There were no differences in
all-cause mortality between Hispanics, Filipinos, and
Whites.
Focusing on those stages of cancer for which guidelines
exist for standard of care (i.e., stage III colon and stages II/
III rectal cancer, data not shown), Blacks had 10% higher
rate of death due to all causes compared to Whites (hazard
ratio = 1.10, 95% CI 1.00–1.21). This hazard rate ratio
ranged from 1.05 to 1.07 and was statistically non-signif-
icant after including each of the SES variables (education,
income, or poverty) into the model. Similarly, for colorec-
tal cancer specific survival, Blacks had 15% higher rate of
death compared to Whites (hazard ratio = 1.15, 95% CI
1.03–1.28), which was completely accounted for by
adjusting for each SES variable. Adjusting for guideline
treatment did not alter the small difference in all-cause or
colorectal specific survival between Blacks and Whites.
Race/ethnic-specific mortality
Proportional hazards modeling was conducted separately
for each racial/ethnic group and the adjusted relative rates
are shown in Tables 5 (disease-specific mortality) and 6
(all-cause mortality). For disease-specific mortality,
among Whites, older age, male gender, single marital sta-
tus, advanced stage, advanced grade, rectal site (compared
to distal), having no surgery, having no chemotherapy,
residence in New Mexico or Utah (relative to San Fran-
cisco Bay Area (SFBA)), and having one or more comor-
bidities were all independently associated with higher
mortality following colorectal cancer diagnosis. Only the
SES variable education showed a statistically significant
gradient of association with mortality among Whites.
Among Blacks, higher mortality was seen among patients
of older age, advanced stage and grade, who had no sur-
gery, no radiation, or no chemotherapy. None of the SES
variables were significantly associated with mortality
among Blacks, although poverty showed non-signifi-
cantly protective effects, and higher education showed
non-significantly adverse effects. Among Hispanics,
increased mortality was associated with advanced age,
male gender, single marital status, advanced stage and
Table 4: Relative rates (and 95% confidence intervals) of dying of any cause for each racial/ethnic group (relative to non-Hispanic 
Whites), SEER, 1992–1996
Variables in model Non-Hispanic
Black 
Hispanic Chinese Japanese Filipino
N = 3,009 N = 1,951 N=851 N=1,094 N=479
Male N = 1,032 Female N = 1,029
1. Race/ethnicity 1.23 (1.18–1.30) 1.01 (0.92–1.10) 0.97 (0.89–1.07) 0.88 (0.80–0.97) 0.78 (0.72–0.85) 0.95 (0.84–1.08)
2. Race/ethnicity + 
sociodemographics1
1.23 (1.17–1.29) 1.03 (0.94–1.13) 1.03 (0.94–1.13) 0.95 (0.86–1.05) 0.95 (0.85–1.06) 1.05 (0.92–1.20)
3. Race/ethnicity + 
sociodemographics & disease 
characteristics2
1.18 (1.13–1.24) 0.96 (0.88–1.06) 0.95 (0.87–1.04) 0.92 (0.83–1.02) 0.97 (0.87–1.09) 0.97 (0.85–1.11)
4. Race/ethnicity + 
sociodemographics, disease 
characteristics, & treatment3
1.14 (1.08–1.20) 0.97 (0.89–1.06) 0.96 (0.87–1.05) 0.88 (0.80–0.97) 0.98 (0.88–1.09) 0.93 (0.81–1.06)
5. Race/ethnicity + 
sociodemographics, disease 
characteristics, treatment, & 
education
1.09 (1.04–1.15) 0.93 (0.84–1.02) 0.93 (0.85–1.02) 0.86 (0.78–0.95) 0.96 (0.86–1.07) 0.90 (0.78–1.03)
6. Race/ethnicity + 
sociodemographics, disease 
characteristics, treatment, & 
income
1.09 (1.04–1.16) 0.94 (0.86–1.04) 0.95 (0.86–1.04) 0.87 (0.79–0.96) 0.98 (0.88–1.09) 0.93 (0.81–1.06)
7. Race/ethnicity + 
sociodemographics, disease 
characteristics, treatment, & 
poverty
1.08 (1.03–1.14) 0.94 (0.86–1.03) 0.95 (0.86–1.04) 0.87 (0.78–0.96) 0.97 (0.87–1.09) 0.92 (0.80–1.05)
8. Race/ethnicity + 
sociodemographics, disease 
characteristics, treatment, & 
comorbidities
1.14 (1.09–1.20) 0.96 (0.88–1.05) 0.95 (0.87–1.05) 0.91 (0.82–1.00) 0.99 (0.89–1.11) 0.95 (0.83–1.08)
1 sociodemographic factors = age and marital status at diagnosis, sex, year of diagnosis, and SEER region
2 disease characteristics = stage, grade, site
3 treatment = surgery, radiation, chemotherapyB
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Table 5: Adjusted1 relative rates (and 95% confidence intervals) of dying of colorectal cancer associated with selected demographic and clinical characteristics, within race/ethnic 
group, SEER, 1992–1996, N = 40,2092
Characteristic 
(referent 
group)
Non-Hispanic
White 
Non-Hispanic
Black 
Hispanic  Chinese Japanese Filipino N = 479
N = 32,825 N = 3,009 N = 851 N = 32,825 N = 1,094 N = 479
Adjusted RR 95% CI Adjusted RR 95% CI Adjusted RR 95% CI Adjusted RR 95% CI Adjusted RR 95% CI Adjusted RR 95% CI
Age (65–69)
70–74 1.08 1.02 -1.15 1.28 1.09 -1.51 1.21 0.97 -1.51 1.14 0.76 -1.70 1.25 0.89 -1.75 0.76 0.43 -1.32
75–79 1.18 1.11 -1.25 1.28 1.08 -1.52 1.35 1.07 -1.70 1.11 0.74 -1.67 1.62 1.12 -2.33 1.60 0.99 -2.59
80+ 1.53 1.44 -1.62 1.35 1.14 -1.59 1.79 1.43 -2.23 1.99 1.34 -2.95 1.77 1.24 -2.53 1.60 1.00 -2.57
Gender (female)
Male 1.06 1.02 -1.11 1.02 0.90 -1.15 1.25 1.05 -1.48 1.17 0.90 -1.54 0.94 0.73 -1.21 1.26 0.86 -1.85
Marital status 
(ever married)
Single 1.14 1.09 -1.19 0.98 0.86 -1.12 1.24 1.04 -1.46 1.33 1.00 -1.76 1.21 0.92 -1.60 0.91 0.62 -1.34
Diagnosis year 
(1992–1993)
1994–1996 0.99 0.95 -1.03 0.94 0.84 -1.06 1.03 0.88 -1.21 1.11 0.85 -1.45 0.86 0.67 -1.10 0.94 0.66 -1.35
AJCC stage (I)
II 2.33 2.12 -2.55 2.65 2.02 -3.47 1.93 1.37 -2.72 3.74 1.94 -7.23 2.37 1.32 -4.24 2.60 1.14 -5.90
III 5.62 5.13 -6.14 4.63 3.54 -6.04 3.89 2.77 -5.47 8.15 4.25 -15.62 7.34 4.27 -12.61 4.52 2.07 -9.85
IV 23.69 21.67 -25.90 20.36 15.70 -26.40 17.04 12.23 -23.74 35.12 18.14 -68.02 41.39 23.68 -72.36 18.22 8.36 -39.70
Unknown 3.63 3.25 -4.06 3.25 2.40 -4.42 2.76 1.76 -4.34 3.77 1.81 -7.85 2.45 1.15 -5.23 3.49 1.39 -8.73
Grade (well)
Moderate 1.22 1.12 -1.32 1.21 0.95 -1.54 1.28 0.91 -1.80 2.46 1.24 -4.91 0.90 0.43 -1.88 0.93 0.43 -2.01
Poor/None 1.86 1.70 -2.03 1.90 1.45 -2.49 1.98 1.38 -2.85 3.65 1.79 -7.45 1.25 0.58 -2.72 1.23 0.53 -2.84
Unknown 1.29 1.17 -1.43 1.26 0.95 -1.68 1.20 0.80 -1.79 1.92 0.88 -4.23 0.69 0.29 -1.62 0.28 0.10 -0.80
Site (rectal)
Distal 0.90 0.84 -0.95 0.86 0.72 -1.03 0.91 0.72 -1.16 0.98 0.69 -1.37 0.99 0.70 -1.39 1.11 0.70 -1.77
Proximal 1.01 0.96 -1.06 0.91 0.77 -1.07 0.89 0.72 -1.11 1.04 0.74 -1.46 0.89 0.63 -1.26 1.35 0.83 -2.19
Surgery (none/
NC direct)
GT Partial LT
Total
0.30 0.28 -0.32 0.28 0.23 -0.33 0.30 0.23 -0.39 0.25 0.16 -0.38 0.18 0.11 -0.29 0.19 0.11 -0.33
Partial 0.27 0.24 -0.32 0.30 0.20 -0.44 0.17 0.09 -0.33 0.66 0.29 -1.49 0.13 0.05 -0.32 0.66 0.22 -1.96
Total 0.37 0.34 -0.40 0.41 0.33 -0.51 0.38 0.28 -0.52 0.41 0.24 -0.70 0.21 0.12 -0.37 0.16 0.08 -0.33
Radiation (none)
Any 0.98 0.92 -1.05 0.78 0.63 -0.97 1.00 0.77 -1.29 0.99 0.62 -1.59 1.21 0.78 -1.88 0.79 0.41 -1.51
Chemotherapy 
(none)
Any 0.89 0.83 -0.95 0.64 0.49 -0.85 0.75 0.60 -0.94 0.76 0.52 -1.10 0.91 0.57 -1.46 1.14 0.67 -1.94
SEER 
region(SFBA)
Atlanta 0.97 0.88 -1.08 0.75 0.60 -0.94 0.25 0.06 -1.02 1.20 0.28 -5.13 - - -
Connecticut 0.97 0.90 -1.04 0.81 0.60 -1.09 0.51 0.32 -0.82 1.58 0.21 -12.07 0.00 0.00 - 1.64 0.34 -7.94
Detroit 0.98 0.91 -1.06 0.91 0.76 -1.09 1.05 0.48 -2.30 0.31 0.04 -2.33 4.24 0.53 -33.64 9.86 1.09 -89.23
Hawaii 0.84 0.68 -1.03 1.43 0.35 -5.89 1.12 0.16 -8.15 0.66 0.41 -1.04 1.21 0.80 -1.83 0.75 0.48 -1.17
Iowa 0.94 0.87 -1.03 0.92 0.54 -1.58 1.32 0.58 -3.04 - - 1.54 0.20 -11.74 - -
LA 0.98 0.91 -1.05 0.84 0.70 -1.01 0.74 0.60 -0.91 1.24 0.92 -1.66 1.32 0.87 -2.02 1.26 0.81 -1.98
New Mexico 1.13 1.00 -1.28 0.93 0.43 -2.02 0.88 0.67 -1.17 - - - -
Seattle 1.02 0.94 -1.11 0.95 0.67 -1.35 0.74 0.36 -1.55 0.93 0.48 -1.82 0.99 0.53 -1.85 0.67 0.25 -1.81B
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Utah 1.12 1.00 -1.26 1.76 0.56 -5.54 0.86 0.47 -1.61 - 0.96 0.23 -4.10 - -
Median income 
quartiles (1st 
highest SES)
2nd 0.91 0.86 -0.98 0.88 0.57 -1.34 0.76 0.53 -1.09 0.87 0.51 -1.49 1.02 0.68 -1.53 1.62 0.94 -2.79
3rd 0.95 0.87 -1.04 0.88 0.55 -1.41 0.77 0.50 -1.18 1.18 0.64 -2.19 1.05 0.63 -1.75 1.89 0.88 -4.09
4th 0.92 0.82 -1.03 0.96 0.59 -1.58 0.87 0.53 -1.42 1.07 0.50 -2.29 1.59 0.82 -3.08 2.54 1.02 -6.33
Unknown 6.31 0.89 -44.94 0.96 0.64 -1.42 0.70 0.49 -1.02 1.46 0.86 -2.47 0.91 0.57 -1.45 2.18 0.87 -5.45
Below poverty 
quartiles (1st 
highest SES)
2nd 1.05 0.99 -1.12 0.77 0.51 -1.17 0.94 0.66 -1.35 1.50 0.89 -2.51 1.03 0.68 -1.56 1.39 0.67 -2.86
3rd 1.08 1.00 -1.16 0.77 0.49 -1.21 1.06 0.70 -1.61 1.38 0.70 -2.70 1.18 0.71 -1.96 1.27 0.59 -2.70
4th 1.06 0.96 -1.17 0.85 0.52 -1.37 1.18 0.73 -1.90 1.59 0.72 -3.50 0.95 0.51 -1.76 0.91 0.34 -2.38
U n k n o w n - -- -- - - - - - - -
Non-HS 
quartiles (1st 
highest SES)
2nd 1.09 1.02 -1.15 1.28 0.89 -1.83 0.79 0.56 -1.11 0.63 0.39 -1.01 0.82 0.54 -1.25 1.65 0.72 -3.77
3rd 1.08 1.01 -1.16 1.32 0.90 -1.93 0.74 0.51 -1.06 0.73 0.42 -1.28 0.85 0.54 -1.33 0.93 0.38 -2.25
4th 1.14 1.04 -1.24 1.32 0.90 -1.95 0.79 0.53 -1.17 0.84 0.46 -1.53 0.98 0.63 -1.54 1.14 0.49 -2.63
Unknown 0.17 0.02 -1.21 - - - - - - - - - -
Comorbidity 
(none)
One or more 1.08 1.03 -1.12 1.09 0.96 -1.23 1.07 0.90 -1.28 1.05 0.75 -1.48 0.98 0.73 -1.33 1.28 0.82 -2.00
1 Adjusted for the other factors in the table.
2Excludes patients with unknown marital status and/or unknown radiation
Table 5: Adjusted1 relative rates (and 95% confidence intervals) of dying of colorectal cancer associated with selected demographic and clinical characteristics, within race/ethnic 
group, SEER, 1992–1996, N = 40,2092 (Continued)B
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Table 6: Adjusted1 relative rates (and 95% confidence intervals) of dying of any cause associated with selected demographic and clinical characteristics, within race/ethnic group, 
SEER, 1992–1996, N = 40,2092
Characteristic 
(referent group)
Non-Hispanic
White
Non-Hispanic
Black 
Hispanic Chinese Japanese Filipino 
N = 32,825 N = 3,009 N = 1,951 N = 851 N = 1,094 N = 479
Adjusted RR 95% CI Adjusted RR 95% CI Adjusted RR 95% CI Adjusted RR 95% CI Adjusted RR 95% CI Adjusted RR 95% CI
Age (65–69)
70–74 1.17 1.12 -1.23 1.28 1.12 -1.47 1.27 1.06 -1.53 1.32 0.94 -1.87 1.25 0.96 -1.63 0.84 0.53 -1.33
75–79 1.43 1.36 -1.50 1.39 1.21 -1.60 1.50 1.25 -1.81 1.42 1.01 -1.99 1.68 1.28 -2.22 2.01 1.35 -2.99
80+ 2.04 1.95 -2.13 1.76 1.54 -2.01 2.07 1.74 -2.47 2.69 1.94 -3.74 2.32 1.77 -3.03 2.20 1.51 -3.21
Gender (female)
Male 1.22 1.18 -1.26 1.12 1.01 -1.24 1.24 1.09 -1.42 1.38 1.11 -1.72 1.26 1.04 -1.53 1.28 0.95 -1.73
Marital status 
(ever married)
Single 1.22 1.18 -1.26 1.10 0.99 -1.22 1.24 1.08 -1.41 1.27 1.02 -1.59 1.23 1.00 -1.52 0.93 0.69 -1.25
Diagnosis year 
(1992–1993)
1994–1996 0.98 0.95 -1.01 0.94 0.86 -1.04 1.00 0.88 -1.14 1.01 0.82 -1.25 0.96 0.79 -1.16 1.02 0.77 -1.36
AJCC stage (I)
II 1.34 1.27 -1.41 1.67 1.41 -1.97 1.32 1.06 -1.65 1.74 1.19 -2.55 1.23 0.90 -1.66 1.80 1.09 -2.96
III 2.26 2.15 -2.38 2.25 1.90 -2.67 2.14 1.71 -2.69 2.94 2.00 -4.31 2.41 1.81 -3.22 2.54 1.56 -4.13
IV 7.69 7.29 -8.11 7.81 6.60 -9.23 7.06 5.65 -8.82 10.10 6.76 -15.08 11.22 8.12 -15.51 7.65 4.65 -12.59
Unknown 1.73 1.61 -1.85 1.81 1.48 -2.22 1.88 1.39 -2.55 2.42 1.53 -3.84 1.27 0.81 -1.98 2.15 1.17 -3.94
Grade (well)
Moderate 1.11 1.05 -1.18 0.98 0.82 -1.16 1.47 1.13 -1.91 1.27 0.81 -1.97 0.91 0.58 -1.42 1.23 0.67 -2.26
Poor/None 1.52 1.43 -1.62 1.54 1.27 -1.88 2.13 1.60 -2.84 1.87 1.17 -3.01 1.23 0.75 -2.03 1.46 0.75 -2.85
Unknown 1.16 1.08 -1.24 1.12 0.92 -1.38 1.32 0.96 -1.80 1.10 0.65 -1.88 0.81 0.47 -1.38 0.70 0.34 -1.45
Site (rectal)
Distal 0.94 0.90 -0.98 0.96 0.83 -1.11 1.00 0.83 -1.20 1.03 0.79 -1.35 1.01 0.79 -1.29 1.02 0.71 -1.48
Proximal 0.99 0.95 -1.03 0.98 0.86 -1.12 0.98 0.83 -1.17 1.02 0.77 -1.34 0.91 0.70 -1.17 1.53 1.06 -2.21
Surgery (none/NC 
direct)
GT Partial LT
Total
0.33 0.31 -0.35 0.30 0.25 -0.35 0.30 0.24 -0.38 0.34 0.24 -0.48 0.21 0.15 -0.31 0.22 0.14 -0.34
Partial 0.39 0.36 -0.42 0.36 0.28 -0.46 0.31 0.21 -0.44 0.67 0.39 -1.16 0.25 0.16 -0.42 0.82 0.41 -1.66
Total 0.38 0.36 -0.41 0.44 0.36 -0.53 0.39 0.30 -0.51 0.46 0.29 -0.72 0.26 0.17 -0.40 0.19 0.10 -0.34
Radiation (none)
Any 0.93 0.88 -0.99 0.78 0.65 -0.95 0.99 0.80 -1.22 1.06 0.72 -1.55 0.99 0.69 -1.40 0.76 0.45 -1.30
Chemotherapy 
(none)
Any 0.81 0.77 -0.86 0.61 0.48 -0.78 0.69 0.57 -0.84 0.78 0.57 -1.08 0.86 0.57 -1.30 0.94 0.59 -1.51
SEER region 
(SFBA)
Atlanta 0.99 0.91 -1.07 0.85 0.71 -1.02 0.53 0.23 -1.21 1.97 0.69 -5.67 - - 0.00 0.00 -
Connecticut 1.00 0.95 -1.06 1.07 0.85 -1.34 0.69 0.49 -0.98 2.65 0.80 -8.83 0.00 0.00 - 1.15 0.26 -5.11
Detroit 0.97 0.92 -1.03 1.10 0.95 -1.28 1.04 0.53 -2.07 0.36 0.09 -1.51 6.60 1.51 -28.80 2.35 0.28 -19.78
Hawaii 0.80 0.68 -0.94 0.74 0.18 -3.01 1.60 0.51 -5.08 0.85 0.60 -1.20 1.20 0.86 -1.67 0.94 0.67 -1.32
Iowa 0.92 0.86 -0.98 0.93 0.60 -1.42 1.35 0.71 -2.58 - - 0.91 0.12 -6.73 - -
LA 1.04 0.99 -1.10 1.00 0.86 -1.16 0.88 0.74 -1.04 1.23 0.97 -1.56 1.34 0.96 -1.89 1.58 1.11 -2.26
New Mexico 1.01 0.92 -1.11 1.05 0.58 -1.89 0.84 0.67 -1.05 1.04 0.13 -8.20 - - -
Seattle 0.99 0.93 -1.05 1.05 0.78 -1.40 0.65 0.36 -1.18 0.98 0.58 -1.66 1.11 0.67 -1.85 0.82 0.41 -1.64
Utah 1.02 0.93 -1.11 1.13 0.36 -3.54 0.85 0.52 -1.38 - 1.00 0.36 -2.84 - -B
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Median income 
quartiles (1st 
highest SES)
2nd 0.94 0.90 -0.99 0.90 0.65 -1.25 0.86 0.65 -1.15 0.95 0.61 -1.48 0.91 0.68 -1.21 1.50 0.99 -2.27
3rd 0.96 0.90 -1.02 1.01 0.71 -1.46 0.98 0.70 -1.37 1.17 0.70 -1.97 0.87 0.60 -1.25 1.79 1.02 -3.15
4th 0.92 0.85 -1.01 1.05 0.71 -1.54 1.14 0.77 -1.67 1.28 0.69 -2.39 1.02 0.63 -1.65 1.82 0.94 -3.54
Unknown 7.10 1.00 -50.37 1.11 0.81 -1.51 0.86 0.64 -1.17 1.62 1.06 -2.47 1.00 0.70 -1.44 1.97 1.03 -3.76
Below poverty 
quartiles (1st 
highest SES)
2nd 1.04 1.00 -1.09 0.80 0.57 -1.10 0.94 0.70 -1.27 1.34 0.88 -2.03 1.27 0.94 -1.71 1.83 1.07 -3.14
3rd 1.06 1.00 -1.13 0.76 0.54 -1.08 1.09 0.78 -1.51 1.15 0.67 -1.96 1.21 0.84 -1.76 1.46 0.81 -2.61
4th 1.09 1.02 -1.18 0.82 0.57 -1.19 1.05 0.71 -1.55 1.25 0.66 -2.35 1.23 0.77 -1.95 1.33 0.66 -2.70
U n k n o w n - - - - - - - -- -- -
Non-HS quartiles 
(1st highest SES)
2nd 1.06 1.02 -1.11 1.17 0.89 -1.55 0.80 0.61 -1.04 0.91 0.62 -1.35 0.95 0.69 -1.31 1.05 0.58 -1.89
3rd 1.09 1.03 -1.15 1.28 0.96 -1.72 0.70 0.52 -0.94 1.00 0.63 -1.58 0.95 0.68 -1.34 0.69 0.37 -1.28
4th 1.13 1.06 -1.20 1.18 0.88 -1.59 0.79 0.58 -1.08 1.09 0.66 -1.79 1.20 0.85 -1.68 0.89 0.50 -1.58
U n k n o w n 0 . 1 6 0 . 0 2 - 1 . 1 3 - - - - -- -- --
Comorbidity 
(none)
One or more 1.50 1.46 -1.55 1.41 1.28 -1.55 1.34 1.17 -1.53 1.35 1.05 -1.74 1.53 1.25 -1.87 1.73 1.26 -2.37
1 Adjusted for the other factors in the table.
2Excludes patients with unknown marital status and/or unknown radiation
Table 6: Adjusted1 relative rates (and 95% confidence intervals) of dying of any cause associated with selected demographic and clinical characteristics, within race/ethnic group, 
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grade, no surgery, and no chemotherapy. Compared to
residents in the SFBA, Hispanics in Atlanta, Connecticut,
and LA experienced decreased mortality (statistically sig-
nificant for Connecticut and LA). Among Chinese, statis-
tically significant factors associated with increased
mortality were advanced age, single marital status,
advanced stage and grade, and no surgery. Among Japa-
nese, the only factors significantly associated with
increased mortality were advanced age, advanced stage,
and no surgery. Among Filipinos, increased mortality was
significantly associated with advanced stage, no surgery,
and living in the lowest income neighborhood. None of
the SES variables were associated with mortality among
Hispanics, Chinese, and Japanese.
Stage had the biggest impact on mortality among all
racial/ethnic groups, followed by surgery. However, varia-
tions in the importance of the other factors were evident
across groups. For example, male gender was associated
with increased mortality in Whites and Hispanics, but not
among Blacks, Chinese, Japanese, and Filipinos. Single
marital status was associated with increased mortality
among Whites and Hispanics, and suggested for Chinese
and Japanese. Histologic grade was a significant predictive
factor of mortality in all groups except for Japanese and
Filipinos. Radiation was associated with mortality only
among Blacks. Chemotherapy decreased mortality in
most groups except Filipinos. Geographic differences in
mortality were also apparent, with relatively higher mor-
tality among Whites in New Mexico and Utah; and lower
mortality among Hispanics in Atlanta, Connecticut, and
LA. Significantly increased mortality was seen with lower
income among Filipinos. Little variation in effect was seen
among the racial/ethnic groups for poverty, except for
slightly increased mortality among Whites and non-sig-
nificantly protective effect among Blacks. Significant asso-
ciations with education were seen only among Whites.
The tests for significant parameter effects across racial/eth-
nic-specific colorectal mortality models (ie, interaction of
parameter with race/ethnicity) showed that the effects of
marital status, stage, and chemotherapy were statistically
significant (p < .025, p < .01, p < .01, respectively) across
the racial/ethnic groups.
Some differences in factors associated with all-cause mor-
tality (Table 6) compared to cause-specific mortality were
evident for each racial/ethnic group, but the most notable
difference was the considerably higher impact of comor-
bidity on mortality, with patients with one or more
comorbid conditions having 34% (Hispanics) to 73%
(Filipinos) higher mortality than patients without any
comorbidities. Another notable difference in all-cause
mortality compared to colorectal-specific mortality is the
higher mortality among males compared to females
across nearly all racial/ethnic groups for all-cause mortal-
ity, whereas higher mortality among males for colorectal-
cancer specific mortality was observed only among Whites
and Hispanics.
Discussion
Our results, based on a large and representative cohort,
show consistently increased mortality (i.e., decreased sur-
vival) among Blacks, compared to Whites, that is partially
but not completely explained by demographic, disease,
treatment, and SES characteristics. This racial/ethnic dis-
parity was evident for mortality due to colorectal cancer as
an underlying cause of death, as well as all-cause mortal-
ity, although the magnitude of the disparity was larger for
colorectal cancer mortality. However, within stage III
colon and stages II/III rectal cancer, for which guideline
treatments are established, survival differences between
Blacks and Whites were considerably smaller and com-
pletely explained by SES. We also found decreased sur-
vival among Hispanic males that was completely
attributable to their being more likely to be diagnosed
with advanced stage cancer, and increased survival among
Japanese that was due in part to their being more likely to
be diagnosed with early stage disease and their place of
residence. Our study extends prior population-based
racial/ethnic studies of colorectal cancer survival by
including additional explanatory factors, including infor-
mation on comorbidities, radiation, chemotherapy, and
area-based SES. In an analysis based on national SEER
data, Chien et al. found persistently decreased stage-
adjusted survival among certain racial/ethnic groups and
postulated that the residual differences were attributable
to SES and/or comorbidities [5]. Using SEER data linked
to Medicare claims, we were able to evaluate the impact of
these factors, plus additional treatment information, on
racial/ethnic differences in survival, and found that
although SES had some impact on Black-White differ-
ences in survival, comorbidities and treatment did not
affect the racial/ethnic differences in survival, at least
among the Medicare-eligible population. In fact, the pres-
ence of comorbidities had minimal impact on colorectal
cancer-specific survival in general, and only among non-
Hispanic Whites. As expected, comorbidities were more
strongly associated with all-cause survival across the
racial/ethnic groups. However, we cannot discount the
possibility that more detailed measures of comorbidity
(e.g., specific conditions or specific combinations of con-
ditions) or a more comprehensive data collection method
(e.g., through medical record review [71]) may have more
significant impacts on survival. Our results confirm, in a
national Medicare population, those from the NCI Black/
White Cancer Survival Study conducted in the mid-1980's
[11], that the Black-White differential in colorectal sur-
vival is partly attributable to stage and SES, but some pro-
portion of the difference remains unexplained. We further
found that this pattern was true for all-cause survival asBMC Cancer 2007, 7:193 http://www.biomedcentral.com/1471-2407/7/193
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well. A recent review and meta-analysis of 10 studies on
colon cancer survival by Du et al. showed that the
adjusted hazard ratio for Blacks compared to Whites was
1.14 (1.00–1.29) for all-cause mortality and 1.13 (1.01–
1.28) for colon cancer-specific mortality [72]. Among
those studies that adjusted simultaneously for age, comor-
bidity, SES, and treatment, the estimates were 1.16 (1.03–
1.32) and 1.30 (1.01–1.67), respectively [72]. These esti-
mates are similar in magnitude to those found in our
study, 1.14 (1.09–1.20) and 1.21 (1.14–1.29), respec-
tively, with our results showing slightly tighter confidence
intervals.
Thus far, it appears that the only studies showing statisti-
cally equal stage-adjusted survival between Blacks and
Whites are those done in a VA setting [4,73], suggesting
that there may be attributes of the VA system (equal access
to screening and treatment, uniform treatment) or its pop-
ulation (similar SES, equal utilization) that are unique
from the general population. An analysis comparing lung
and colon cancer outcomes between Black and White VA
patients who received uniform evaluation and treatment
showed that cancer outcomes were similar despite lower
SES (individual-level) among Blacks [74]. Shavers and
Brown synthesized several studies examining racial/ethnic
disparities in colorectal cancer treatment and found that
population-based studies tended to find significant racial/
ethnic differences in treatment, whereas studies showing
no racial/ethnic differences tended to be non-population-
based, from a single clinic or locality, or of VA popula-
tions [75]. A recent study of a cohort of insured patients
found that Black-White differences in survival were
explained primarily by stage and receipt of surgery [76]. In
a conceptual framework illustrating potential barriers to
the receipt of optimal cancer treatment, Shavers and
Brown advocated the importance of "structural barriers",
which include presence and type of insurance coverage,
institutional and geographic factors [75]. In fact, a
number of recent, population-based studies have demon-
strated a modest but independent effect of surgeon and
hospital characteristics [8,77] and of specific types of
health care coverage [10], but, to our knowledge, these
factors have not been evaluated for their impact on racial/
ethnic differentials in survival following colorectal cancer.
The increased survival of Japanese compared to other
race/ethnic groups and other Asian subgroups has been
noted in other studies [5,19,20]. We found that about half
of the survival difference between Japanese and Whites
was due to earlier stage at diagnosis among Japanese, the
other half due to the greater proportion of Japanese living
in Hawaii and the increased survival in Hawaii seen in
some racial/ethnic groups. Choe et al found, in a survival
analysis of national SEER data (with imputed nativity
data) that US-born Asians experienced more favorable
survival than foreign-born Asians [17]; as only 28% of
Japanese (in California) are foreign-born [78] and they
tend to be the most acculturated of other Asian subgroups,
future research might focus on specific factors associated
with being US-born Asian, or Japanese in particular, that
confer a survival advantage. In a previous paper, we noted
decreased stage-adjusted survival among Filipino males
[19]; evidently, the poor survival was limited to both ear-
lier years of diagnosis and younger Filipino men, thus,
this pattern was not seen in this analysis.
Our race/ethnicity-specific survival models also revealed
differential effects of some of the covariates on colorectal-
specific and all-cause survival within each racial/ethnic
group. Surprisingly, the area-based SES variables did not
appear to be associated with colorectal cancer nor all-
cause survival in most racial/ethnic groups. Only the
measures poverty and education demonstrated margin-
ally significant effects on survival among Whites, and
income among Filipinos. The differential effect of marital
status is also interesting: whereas single patients tended to
have decreased survival than those who were married, this
was not true for Blacks nor Filipinos. The quality of mari-
tal status information in the cancer registry is uncertain, so
these results should be cautiously interpreted, but the
beneficial effects of being married on cancer survival has
been previously explored and is hypothesized to be due to
greater spousal social support [79]. We also observed sig-
nificantly decreased all-cause survival among males com-
pared to females in nearly all racial/ethnic groups. As this
gender difference was not seen for colorectal-specific sur-
vival among most racial/ethnic groups, this finding sug-
gests that, relative to females, male colorectal patients
experienced decreased survival due to causes of death
other than colorectal cancer.
There were also differences in the effects of tumor charac-
teristics and treatment. For example, histologic grade,
reflecting tumor aggressiveness, did not appear to impact
survival among Japanese and Filipinos. Although having
any extent of surgical resection was uniformly associated
with increased survival across all groups, a beneficial
effect of radiation was only seen among Blacks. Chemo-
therapy was associated with increased survival in all
groups, but not in Asians. These racial/ethnic differences
in treatment impact on survival may reflect differential
distributions of stage and colorectal cancer subsite among
race/ethnic groups [63,75], or of a differential selection by
physicians of healthier patients to receive these treatments
[71,80]. In addition, because our measures of surgery,
radiation, and chemotherapy are crude, the differences
may also reflect differences in the quality of treatment.
Further study examining survival patterns within specific
stage and subsite, and incorporating more specific treat-
ment data would be helpful. Overall, the results fromBMC Cancer 2007, 7:193 http://www.biomedcentral.com/1471-2407/7/193
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these race/ethnicity-specific analyses support the value of
evaluating each group on its own, as this type of analysis
may reveal patterns that can result in more targeted and
meaningful prevention efforts and strategies for improv-
ing survival for each group.
Stage remains the single most independently predictive
factor on survival following diagnosis of colorectal cancer
across and within racial/ethnic groups. For persons aged
50 or older, the American Cancer Society recommends
one of five screening schedules, depending on the modal-
ity (fecal occult blood test (FOBT) yearly, flexible sig-
moidoscopy or barium enema every 5 years, or
colonoscopy every 10 years) [81]; however, data based on
the California Health Interview Survey showed that only
53% of respondents reported having had an FOBT in the
past year or sigmoidoscopy/colonoscopy in the past 5
years [82]. Moreover, Latinos reported lower screening for
colorectal cancer (37%) compared to 56.4% among
Whites [82]. Research on promoters and barriers to cancer
screening consistently show that, among Asians and Lati-
nos, screening is lower among recent migrants with lim-
ited English proficiency [82-87]. There is ongoing research
to examine strategies to increase screening in different cul-
tures [88]. Since early detection could potentially reduce
some of these differences in survival, particularly among
Hispanic men, it is clearly important to learn about barri-
ers to screening among specific communities and to eluci-
date the most effective strategies for promoting screening
in these communities.
Although our study provided a comprehensive evaluation
of multiple factors in relation to survival across and
within race/ethnic groups, our results may be limited by
the quality of some of the SEER and Medicare data. For
example, research of race/ethnic misclassification in med-
ical admissions and registry data shows that although
there is high consistency between self-report and hospital
data for Whites and Blacks, consistency is lower for other
groups, in particular Hispanics, American Indians, and
certain Asian subgroups [25,33,89]. Our study may also
be compromised by completeness of surgery, radiation,
and, in particular, chemotherapy data. Comparisons of
surgery and radiation recorded in SEER with other sources
(Medicare admissions, physician survey) show that regis-
try data are, for the most part, complete and do not vary
greatly with regards to race/ethnicity [60,61,90-92]. War-
ren et al showed that physician claims data capture about
70% of the chemotherapy administered among colorectal
cancer patients [62]; however, the prevalence of receipt of
chemotherapy and of guideline treatment are lower than
those seen in other studies [64,65,76] raising concerns
about some under-ascertainment of chemotherapy in our
data. Thus, we cannot discount the idea that our results,
particularly the Black-White differences in survival, may
be affected by completeness in our treatment data, partic-
ularly if it is differential across racial/ethnic groups. Our
analyses could benefit from the addition of potentially
useful information on insurance, hospital and physicians
characteristics to investigate institutional factors that cre-
ate unequal access to medical care [8,9,77,93,94]. Addi-
tionally, although information on colorectal cancer
screening is theoretically available from Medicare claims
data, insurance coverage for these screening modalities
went into effect only recently [95,96] and the complete-
ness may be further compromised by how providers bill
for these procedures. Furthermore, we included patients
diagnosed with colorectal cancer during the years 1992–
1997 to allow for observation of a reasonable amount of
time between diagnosis and follow-up; however, racial/
ethnic survival patterns, particularly between Blacks and
Whites, may have changed during this time. Data from the
SEER registries showed that while 5-year survival
improved among White males and females and Black
females between 1992–1997 and 1997–2002, it has wors-
ened slightly among Black males. Thus the survival dispar-
ity between Black and White males has increased [14],
making the implications of our analysis even more note-
worthy.
Conclusion
Despite the inherent limitations in the data source used in
the analyses, our study has strengths in being a compre-
hensive analysis of colorectal cancer survival – both in the
enhanced inclusion of specific racial/ethnic groups and
prognostic factors, gained from linkage to Medicare and
Census data. We found evidence that, in the older Medi-
care population, racial/ethnic disparities in colorectal can-
cer survival may be reduced by increasing access to
screening. However, among Blacks, survival disparities
compared to Whites and other racial/ethnic groups persist
even after accounting for a comprehensive set of sociode-
mographic, clinical, and treatment characteristics. Wil-
liams has proposed that the persistently worse health
outcomes among Blacks may be attributable to broader
societal discrimination in neighborhoods (i.e., residential
segregation) and in health care delivery (i.e., institutional
discrimination) [97,98]. With regards to colorectal cancer
survival, additional research in areas that have received
less attention, such as structural and institutional barriers
[75,77], and of factors that have been proposed recently as
having significant impacts on survival, including physical
activity [99,100] and vitamin D [101-103], is necessary to
identify the factors and mechanisms leading to the poorer
outcomes among US Blacks. Population-based cancer reg-
istry data continue to be an invaluable resource for iden-
tifying and addressing racial/ethnic health disparities,
however, expansion of the data through collection of
additional data items and/or linkage to other data sources
[104] is necessary for looking beyond traditional explana-BMC Cancer 2007, 7:193 http://www.biomedcentral.com/1471-2407/7/193
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tions, particularly if we hope to be able to reduce dispari-
ties in cancer outcomes.
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